The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Roflumilast cream receives FDA approval for use in pediatric patients with plaque psoriasis
On October 6, 2023, the U.S. Food and Drug Administration (FDA) approved roflumilast cream 0.3%,1 a topical phosphodiesterase-4 inhibitor,2 for use in pediatric patients aged between 6 and 11 years with plaque psoriasis.1 This follows the approval of roflumilast cream in patients with plaque psoriasis aged 12 years or older in July 2022.2
This expanded indication follows positive results from a 4-week maximal usage systemic exposure study in pediatric patients with plaque psoriasis.1 Safety and efficacy data were similar to the DERMIS-1 and DERMIS-2 trials (NCT04211363; NCT04211389) in adult patients with plaque psoriasis. Future studies will assess roflumilast safety and efficacy in patients aged 2 to 5 years old.
Roflumilast cream is currently the only available treatment for plaque psoriasis that is specifically indicated for use in intertriginous areas.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content